Raloxifene is a medication used to treat postmenopausal osteoporosis and the risk reduction of invasive breast cancer in post-menopausal women. Osteoporosis represents an increased risk for developing fractures. Raloxifene is a selective estrogen receptor modulator with an estrogen-agonistic effect on bone receptors. This activity outlines the indications, action, and contraindications of raloxifene as a valuable agent in the treatment of osteoporosis. In addition, this activity will highlight the mechanism of action, adverse event profile, and dosing pertinent for members of the interprofessional team in patients treated with raloxifene.
Identify the mechanism of action of raloxifene.
Describe the adverse effects of raloxifene.
Review and select appropriate monitoring parameters for patients treated with raloxifene.
Outline interprofessional team strategies for improving care coordination and communication for patients on raloxifene therapy where appropriate, including follow-up monitoring, and improve outcomes.
- Formulated and packaged to prevent evaporation in storage.
- Built in graduated 1mL pipette for accurate measurement.
- UV resistant glass bottle to minimize heat degradation.
- Tamper-proof seal to ensure safety in transit.
Products are furnished for LABORATORY RESEARCH USE ONLY. This product should only be handled by qualified, and licensed professionals. The product may not be used as a drug, agricultural or pesticidal product, food additive or household chemical – and may not be misbranded as such. All information on this website is available for educational purposes only. Bodily introduction of any kind into humans and/or animals is strictly forbidden by law.
Raloxifene is an FDA-approved second-generation selective estrogen receptor modulator (SERM), a drug with an estrogen-agonistic effect on bone, increasing bone mineral density and mass by decreasing bone resorption. It is indicated in the treatment and prevention of postmenopausal osteoporosis.
Raloxifene is also indicated for the risk reduction of invasive breast cancer in postmenopausal women, demonstrating a high risk for invasive breast cancer or women with osteoporosis. The definition of high breast cancer risk is one or more first-degree relatives with breast cancer, or at least one breast biopsy showing lobular carcinoma in situ (LCIS), or atypical hyperplasia, or a 5-year predicted breast cancer risk of more than 1.66%.
Studies are underway on raloxifene as an adjuvant treatment for postmenopausal women with schizophrenia. It shows particularly promising results in mild presentations of schizophrenia.